Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 20,229 put options on the stock. This is an increase of approximately 364% compared to the average volume of 4,356 put options.
Wall Street Analysts Forecast Growth
RETA has been the topic of a number of analyst reports. SVB Securities lifted their target price on shares of Reata Pharmaceuticals from $35.00 to $75.00 in a research note on Wednesday. Robert W. Baird increased their target price on Reata Pharmaceuticals from $40.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday. Citigroup raised their target price on shares of Reata Pharmaceuticals from $53.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday. Cantor Fitzgerald increased their target price on shares of Reata Pharmaceuticals from $61.00 to $121.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Barclays raised their target price on Reata Pharmaceuticals from $50.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $95.00.
Reata Pharmaceuticals Stock Up 198.9 %
Shares of Reata Pharmaceuticals stock opened at $93.17 on Thursday. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of -10.88 and a beta of 1.25. Reata Pharmaceuticals has a 52-week low of $18.47 and a 52-week high of $95.00. The company’s 50-day simple moving average is $40.77 and its 200-day simple moving average is $34.12.
Hedge Funds Weigh In On Reata Pharmaceuticals
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
- Get a free copy of the StockNews.com research report on Reata Pharmaceuticals (RETA)
- Jack in the Box Pops On Tasty Results, Robust Outlook
- How Low Can Lowe’s Companies Go?
- Ambarella: An AI Play In The Making
- Wendy’s Price Firms After Sizzling Quarter And Juicy Outlook
- Terran Orbital’s New $2.4 Billion Contract is a Game Changer
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.